London-based Clinigen is adding to its roster of biopharma services with the acquisition of regulatory affairs specialist Kinesys Consulting.
The deal will give Clinigen “expanded capabilities to help its clients navigate the complexities of pharmaceutical development and commercialisation,” according to an Aug. 6 statement from the company.
Kinesys specializes in strategic regulatory affairs, regulatory/medical writing and medical device services for its life sciences clients.
In what Clinigen describes as a “strategic acquisition,” the deal “strengthens Clinigen's ability to offer clients comprehensive high value services across the entire drug development and commercialisation lifecycle.”
The Kinesys team will now integrate into Clinigen’s Lifecycle Services division.
“At Kinesys, we specialise in guiding clients through the intricacies of regulatory strategy and execution for drugs and medical devices, as well as providing a high-quality medical/regulatory writing service,” said co-founder of Kinesys Consulting Elaine Murphy in a release.
“This strong foundation allows us to support our clients throughout the entire development journey. By joining Clinigen, we're excited to offer both our existing clients and Clinigen's a seamless path from navigating initial regulatory hurdles to achieving successful market access.”